Comparative Pharmacology
Head-to-head clinical analysis: FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE versus TRICHLOREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE versus TRICHLOREX.
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE vs TRICHLOREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosinopril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Trichlorex is a thiazide-like diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing water excretion.
1 tablet (fosinopril 10 mg/hydrochlorothiazide 12.5 mg or fosinopril 20 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: fosinopril 80 mg/hydrochlorothiazide 50 mg per day.
Oral: 500 mg once daily after the evening meal; sustained-release: 500 mg once daily at bedtime.
None Documented
None Documented
Fosinoprilat: 11.5 h (terminal); Hydrochlorothiazide: 6-15 h (biphasic, terminal phase 10-15 h).
Terminal elimination half-life is 8-12 hours in adults; prolonged to 20-30 hours in severe renal impairment (creatinine clearance <30 mL/min).
Fosinopril: 45% renal, 55% biliary/fecal; Hydrochlorothiazide: >95% renal (unchanged).
Renal (90% as unchanged drug, 10% as trichloroacetic acid and trichloroethanol); minor biliary/fecal (less than 1%).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic